Weekly Insight: Tipster Scrutiny on TUI, GSK and Barratt

Published 97 days ago

Travel operators TUI AG (TUI) and Thomas Cook Group (TCG) both featured in the top five most frequently tipped companies over the last seven days in a busy week for trading updates. Homebuilders Barratt Developments (BDEV) and RedRow (RDW) also received an influx of tips after both released interim results, while there was increased tip activity for GlaxoSmithKline (GSK) and Smith & Nephew (SN.).

This Giant Pharma Has A Split in Mind Which Should Be Healthy for Shareholders

Published 116 days ago

Hello Share Trudgers. Though treading in my erudite colleague Chris Bailey’s shoes, I thought it might be useful to have another take on GlaxoSmithKline (GSK) This giant pharma is a big part of my ‘safer’ Footsie portfolio (I put safer in quotes as some of my biggest losses ever have been members of the big 100 club)...

The Curious Case of the Washington Stand-Off and a Whiz Bang Firm from Hemel Hempstead

Published 120 days ago

Hello, Share Swappers. As you know, Big Donald’s stand-off with opposing politicians has led to the curtailment of government activities in Washington. You might not be aware that some British firms are affected by this curious situation. For example, those federal officials who give go-aheads to pharmaceutical companies have not been able to act as speedily as they’d like to...

Shareholders Should Benefit As this Giant Pharma Climbs Into Bed with an American Rival

Published 154 days ago

Hello, Share Whackers. My more inspirational Shareprophets colleague Chris Bailey has already posted on an exciting development for GlaxoSmithKline (GSK). As this is a share I’ve also pushed for some years, allow me to add my own humble thoughts...

Welcome to your FTSE 100 broker Christmas lunch

Published 155 days ago

Back in the day, I used to be an institutional fund manager and did go on a number of brokerage lunches at around this time of year. The essential underlying aim of these lunches did not change for years: a thank you for business given during the year...and a pitch or ten about stocks that could be bought (or sold) early the next year in order to keep that commission flow going (and from the broker's perspective hopefully building). It seemed to me that the ideas took a very simple form: buy the underperformers and sell the outperformers. Well who does not like a bargain or - indeed - to take profits? So from an akin premise - but with an added slice of cynicism (and no need to elicit your brokerage commission flows!) - what does a 'brokerage lunch list' throw up as interesting in December 2018 looking ahead into 2019?...

Do I need to make an apology to dividend muncher favourite GlaxoSmithKline?

Published 156 days ago

Much has been said or written about GlaxoSmithKline (GSK) during 2018 and my most recent contribution back in July suggested that a divisional split-up was a spoof. Well today's announcement that Glaxo has formed a joint venture vehicle with US pharma behemoth Pfizer for their respective consumer health arms (with ownership split 68%/32% in favour of Glaxo) appears at face value like a step in the right direction for under pressure CEO Emma Walmsley and team…

GlaxoSmithKline Is a Medical Giant With a Growing Market in Vaccines and a Nice Divi to Sweeten the Pill

Published 220 days ago

Hello, Share Pinchers. One of the most attractive sectors to invest in for those who like to inhabit the moral high ground is medicine. Who would not want to try to alleviate pain and suffering in Britain and the world? Yes, there can be worries that some companies are not as good as they might be in curbing the costs of treatment and drugs, but on the whole it’s a satisfying area of investment.

What Hammerson, BT Group and GlaxoSmithKline are really trying to say...

Published 303 days ago

I know the summer heat is starting to get to everyone but today's regulatory and brokerage output is a little...coy on a few names I have written about in the past few months. So in the spirit of helping market is what three large corporate names are trying to say...

Oxford Bags Some Big Deals and that Share Price May Rise Even More

Published 346 days ago

Hello, Share Nappers. It was a long time ago that I sold them, but shares in Oxford BioMedica (OXB) have started doing rather well. And that is becoming more unusual for small pharmaceutical companies. So the firm must be doing something right.

Bonkers Glaxo buys expensively let alone splits-up

Published 423 days ago

Last week I hoped that GlaxoSmithKline's (GSK) backing away from a mega deal which would have seen them splurge US$20bn odd on the consumer unit of American pharma name Pfizer was an early sign of a new commitment to not building an empire and maybe even considering splitting the company up into its constituent parts.  Well that slammed that door closed today with news that they are buying out the shares in a consumer healthcare jv they have with the Swiss pharma giant Novartis for a cool US$13 billion. 

Glaxo, Smiths Group - drawing up a list for 2019 tips of the year!

Published 427 days ago

I was hoping for a big bit of volatility in shares in Next (NXT) today but its full year update is - in the wider scheme of things - pretty worthy. Why?

Market “crashing”: a few thoughts and 30 interesting yields for dividend munchers

Published 464 days ago

Warren Buffett always tells us that his intended investment holding period is forever, that he buys stocks he would be happy to hold if the market closed down for five years. I guess, then, if you’re  Warren Buffett then the market travails of the last few days won’t bother you. If you’re not Mr Buffett I offer a few thoughts.

Concerns over future dividends offer a good buying opportunity in GlaxoSmithKline

Published 538 days ago

The big pharmaceutical companies have traditionally been a fairly safe bet for a steady source of income over the years, and through the peaks and troughs in the markets.

It Should Pay to Stick With AstraZeneca, but Patience Is Needed

Published 662 days ago

Hello, Share Spooners. Given the ageing and less healthy world population, I have often said that the big pharmaceuticals offer a buying opportunity. But as usual with medical advances, progress has been slow. I hold shares in GlaxoSmithKline (GSK). But although I’ve often been tempted to dive into its big rival AstraZeneca (AZN), I have resisted the urge. Now I’m rather glad I did.

Is GSK's Boat Finally Coming In? It Seems Healthy Enough

Published 724 days ago

Hello Share Shapers. Every so often I look at that great British pharmaceutical giant, GlaxoSmithKline (GSK) and I usually notch it up as a buy. Despite the fact that it has not been quite as successful a punt as I had hoped, I am still well up on my three year old purchase. The dividend, which I have at nearly 5% is also useful. And I was gratified that it was one of the perkiest  Footsie risers on Friday.

This Big British Pharma is Set to Grow as our Health Slumps

Published 836 days ago

Hello Share Punchers. I’ve just heard on the BBC more woes facing British hospitals. It does seem that most of them now have no slack and routine operations keep being put off, with nowhere to send many patients once beyond the surgeon’s knife.

ShareProphets Share Tips of the year Number 18 - buy Wishbone Gold says Tom Winnifrith

Published 875 days ago

You want your share tip of the year to have the potential to double or treble. You will not get that with GlaxoSmithKline (GSK). Equally it is incredibly unlikely that you might lose 75% of your cash on Glaxo. Elephants do not gallop eith forwards or backwards. My third tip of the year is a stock that could lose 75% and become a cash shell. But it is also one that could easily treble and I think he odds are on the treble not the collapse. I refer to Wishbone Gold (WSBN)

Glaxo appoints Emma Walmsley, a bird, as its CEO - this is demographics not legislation in play

Published 976 days ago

It is great to see that one of the UK's largest companies, GlaxoSmithKline (GSK) has a new CEO who has a cracking CV and and has without doubt been appointed on merit. Oh... and she wears a skirt, that is to say that she is a woman, Emma Walmsley. I wish her well. Emma demonstrates a couple of things which will horrify the liberal left.

As Cancer Treatments Advance it Could Be Time to Look Into AstraZeneca and GlaxoSmithKline

Published 1081 days ago

Hello Share Pitchers. My parents were so frightened of cancer that they refused to utter the word. As a result I had never even heard of the affliction until I was an advanced teenager. These days we all still fear the condition, but we perhaps should not do so as much as we used to. This is because treatments are becoming more effective year on year. It is still an appalling killer, though.

Worried about market turmoil over Brexit? Then take a look at GlaxoSmithKline.

Published 1097 days ago

With uncertainty over Brexit and possible market turmoil around this event, and assuming you’re not planning to move to cash, now would seem like a good time to add some defensive shares to your portfolio.

Try a Fiesty Firm Which Helps the Polluted World to Breathe: Vectura.

Published 1133 days ago

Hello Share Munchers. Time to re-visit another bio techie, I think. This weekend, I give you Vectura (VEC). My thinking as usual is that we have a world population that gets sicker by the minute. It’s also getting older which means the raft of complaints us oldies have to suffer is getting vaster, too.

Vectura Could be a Breath of Fresh Air in your Biotech Portfolio.

Published 1207 days ago

Hello Share  Shiners.  All right, this is another article on a promising bio science outfit. Yes, my support for companies which push through the frontiers of medicine is undiminished in 2016.

Want Some Consolation for an Unhealthy New Year? Take a Peek at GlaxoSmithKline.

Published 1240 days ago

I hope you have a happy and healthy New Year. Though, especially if you are of a certain age, I fear the odds are against it. My Christmas cards usually contain letters from old friends and relatives. And I was shocked to learn that one of them had almost lost her sight, another is on crutches awaiting knee transplants, another has breast cancer and so on.

As Oilers and Miners Squirm, the Leisure Industry Piles on Share Value.

Published 1262 days ago

Hello Share Trippers. Oh dear! The price of crude oil drops to less than 40 dollars a barrel.That’s really nasty and we can blame OPEC for refusing to cut down on the amber nectar it has for sale.

It’s Beginning to Look Like Christmas - and the usual Yule Share Boom.

Published 1267 days ago

Hello Share Surfers. The old Footsie fell 2.5% on a day which began rather well. Why? Well, according to the media, the European Central Bank 'failed to deliver on market expectations for an increase in monthly asset purchases.’

GlaxoSmithKline is a strong buy at these levels

Published 1341 days ago

The recent big drops in many leading stock market indices, including the FTSE100, is giving an opportunity to pick some stocks up at a bargain price. I think that GlaxoSmithKline (GSK) definitely falls into that category and its current share price of around 1285p – the lowest levels since mid-2011 – offers a great long term buying opportunity for this FTSE100 listed pharmaceutical company.

Big cap deal smackdown: Glaxo and BT Group

Published 1568 days ago

If you want to make money in large cap shares then you have to spot the big changes.  Deals can be such transforming events…and updates from two big FTSE-100 heavyweights over the last day or so are noteworthy. 

British American Tobacco Chairman Adds to His Stock – that is a (smoke) signal to you

Published 1597 days ago

Richard Burrows, the chairman of British American Tobacco (BATS), has increased his ownership of the company with a significant £176,017 purchase. 5,000 shares were bought at a price of 3520.34. He now has 15,000 shares in the business.

Mark Howitt’s share tips of the year No2 – GlaxoSmithKline

Published 1604 days ago

After some careful thought I have selected GlaxoSmithKline (GSK) as one of just two of my Prime Share Selections for 2015. Being honest, I find it difficult to pick two which really should be the best of all shares, but I am fairly confident GlaxoSmithKline will perform well in 2015.

Gloom Lifts as FTSE 100 Has Record Performance!

Published 1615 days ago

Shares can be a real rollercoaster ride. ‘Mr Market’ can perform such gyrations for no logical reason, but this can still have a serious effect on our wealth. This week £62 billion was added to the value of the FTSE 100, as the index enjoyed its best week in three years.

Market Meltdown Throws Up Massive Bargains

Published 1623 days ago

I’ve already mentioned how the FTSE dropped a whopping 2.49% on Friday. I’ll be directly honest with you now, it was quite painful to watch. Sometimes owning shares is like living in a surreal dream, sometimes it’s like experiencing a nightmare. It’s hard to comprehend how you can be worth so much less at the end of the day... for doing nothing.

GlaxoSmithKline Fails to Sell Its Established Products Portfolio. What does this say about the Shares?

Published 1626 days ago

GlaxoSmithKline (GSK) has recently announced that it has failed to sell its established products portfolio. This is basically a bunch of North American and European drugs that have recently lost their patent protection.

Maybe Time For a Punt in the House of the Rising Sun

Published 1633 days ago

Hello Share Samurai. There's a growing case for turning Japanese. I mean in the buying of Oriental shares.

Invest in Shares and Experience Living in a Surreal Dream

Published 1643 days ago

I’m writing this article mainly for people who haven’t invested in shares yet, or those who haven’t put much of their wealth into equities. This year has been quite a buying spree for me... as of now over two thirds of my total worth is in shares, and around 75% of my quickly accessible wealth.

Being an Investor and writing about shares

Published 1647 days ago

I’m sorry it’s been a while that I’ve written. I have been doing lots of other things, mainly to get more money to invest in shares, but I still should have written more. I’ve been doing lots of ‘active research’ including travelling to shareholders meeting and more ‘in depth’ personal research into companies that I own, but that’s still no excuse. I’ve kind of had a bit of ‘writers block’ but there’s something interesting on my mind now which hopefully I can express.

Sorry, Smiths Group – It Was All a Big Conking Mistake.

Published 1668 days ago

Hello Share Shapers. They say that it's the payment of dividends, rather than striking it lucky occasionally, that leads to making real money on the Stock Exchange.

Drugs Giant Takes a Chance – and So Might You.

Published 1673 days ago

Hello Share Pounders. At the risk of sounding again like a soft goody goody (TW Note - perish the thought), I want to commend to you the warm feeling that can be achieved by investing in big pharma companies.

Glaxo Results Boosts Share Price - but still a buy

Published 1673 days ago

It’s been a torrid year for GlaxoSmithKline’s (GSK) share price. From a year high of 1706p, it recently fell to a low of 1296.p. However there was some much needed cheer yesterday, when the shares, trading at around 1330p, were lifted to over 1400p briefly, before closing at 1385.5p. The catalyst? Publication of its results at 12 o’clock which beat expectations.

At 549p Banco Santander is Good Value Again!

Published 1675 days ago

It is good to see the FTSE 100 rise today, but not all companies are joining in on the fun. Shares in British American Tobacco (BATS) have fallen, so have shares in GlaxoSmithKline (GSK) and Banco Santander (BNC) shares are basically flat at 549p.

GlaxoSmithKline continues work to develop Ebola Vaccine

Published 1676 days ago

Ebola is certainly everywhere on the news at the moment. The epidemic continues to spread like wildfire, and more people are dying all the time. Thankfully, GlaxoSmithKline (GSK) is continuing its work on a vaccine which should help stem the spread. Today it issued a press statement, opening with the following:

Investing is a Life Long Pursuit – ref GlaxoSmithKline and BP

Published 1689 days ago

The FTSE took quite a hit yesterday. It closed down by 1.04% at 6495.58. Yet there is good news- I believe there are a number of buying opportunities around at the moment! For the long term investor a general market sell off should be viewed as an opportunity not a cause for alarm. So here are two stocks that I am nowlooking to add to thanks to the market wobble.

Practical Tips you can take From One Up on Wall Street Part Four

Published 1698 days ago

Peter Lynch makes an obvious but interesting point about the PE ratio of shares in his classic One Up on Wall Street. “If you buy back shares in a company selling at two times earnings (a p/e of 2), you will earn back your initial investment in two years, but in a company selling at 40 times earnings (a p/e of 40) it would take forty years to accomplish the same thing. Cher might be a great-grandmother by then. With all the low p/e opportunities around, why would anybody buy a stock with a high p/e?”

GlaxoSmithKline- a Good Addition to Your Portfolio

Published 1724 days ago

GlaxoSmithKline (GSK) shares are currently trading at 1457p on a PE of 13.1 and a dividend yield of 5.35%. I’ve only fairly recently bought into the company, here is a table at between 1379p and 1556.6p, So I am not exactly quids in yet but this is a long term play.

Feel-Good Medical Shares Could Hit Higher Temperatures.

Published 1726 days ago

Hello Share Collectors: There is a growing case for investing in companies, which sell or look for medical cures. I think the big British pharma companies are undervalued and worth a punt.

GlaxoSmithKline good value at 1428p

Published 1760 days ago

The fall in the GlaxoSmithKline (GSK) share price to1428p is a story in its self.  Not only is it back to where it approximately was in 2013 but it now stands on what I perceive to be a three year support level. (Have a look for yourselves.) If so, will the share price hold there and is it a reason to buy the shares as cheap at 1428p on an historic dividend yield of 5.4% and on the basis that “there will always be a Glaxo”; an approach that has generally speaking been a good point to buy the shares when the news looks bleakest?

Invest in us we are ethical – just another AIM Con

Published 1762 days ago

Malcolm Stacey is a very good man. He is an ethical operator in every way. But when looking at the nest of snakes that is AIM that is not perhaps the greatest attribute an investor can have. The Vipers lure you with a line about ethical investing but 99% of the time it is just so much cock.


About ShareProphetsTerms of ServiceForgot My Password
Contact UsPrivacy PolicyForgot My Username
Advertise With UsCookie PolicyResend Account Validation Token
Send Us A Tip

Data by ADVFN / Site by Everywhen /